| Literature DB >> 35445130 |
Xiaomao Li1, Yan Liu1, Siyi Wang1, Yikai Jiang1, Adnan Mohammed Algradi1, Yuanyuan Zhou1, Juan Pan1, Wei Guan1, Haixue Kuang1, Bingyou Yang1.
Abstract
The aerial parts of Bupleurum Chinense DC. aromatic oil (BAO) were a well-known Chinese herbal medicine plant extract used to treat epilepsy. This study aimed to explore the therapeutic effect of BAO on kainic acid- (KA-) induced epileptic rats and the possible mechanism of its antiepileptic effect. The composition and content of BAO were analyzed by GC-MS, and BAO was administered orally to alleviate the epileptic behavior induced by KA brain injection. The behavior of epileptic rats was determined by Racine grading criteria. And hematoxylin-eosin staining (HE), Nissl staining, immunohistochemistry, Elisa, Western blot, and other methods were used to study the antiepileptic mechanism of BAO, and the possible mechanism was verified by the epileptic cell model of hippocampal neurons induced by the low-Mg2+ extracellular fluid. BAO was mainly composed of terpenoids and aliphatic compounds. And BAO could improve KA-induced epilepsy-like behavior, neuroinflammation, and neurotransmitter abnormalities in the hippocampus. Furthermore, BAO could regulate the expression of GABA, NMDAR1, Notch1, and MAP2 to improve the symptoms of epilepsy. These results were also validated at the cellular level. These results indicated that BAO could alleviate the epilepsy-like behavior through the action of the Notch/NMDAR/GABA pathway.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35445130 PMCID: PMC9015862 DOI: 10.1155/2022/1234612
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
The chemical components of BAO by GC-MS.
| No. | tR (min) | Name | Molecular formulae | Molecular weight g/Mol | Fixed area |
|---|---|---|---|---|---|
| 1 | 14.03 | (H) Pyrrole-2-carboxaldehyde | C5H5NO | 95.10 | 23.17 |
| 2 | 14.58 | (H) Camphene | C10H16 | 136.23 | 2.36 |
| 3 | 15.39 | (H) Bicyclol [3.1.0] hex-2-ene | C10H16 | 136.23 | 2.35 |
| 4 | 15.55 | (H) | C10H16 | 136.23 | 13.52 |
| 5 | 15.87 | 2-pentylfuran | C9H14O | 138.21 | 6.15 |
| 6 | 17.09 | 1-Methyl-2(-1-methyl)-benzene | C9H11 | 119.19 | 44.34 |
| 7 | 17.26 | (R) D-limonene | C10H16 | 136.23 | 31.72 |
| 8 | 19.45 | (H) Camphenol | C10H16O | 152.23 | 6.71 |
| 9 | 19.54 | (H) 2(10)-pinen-3-one | C10H14O | 150.22 | 4.19 |
| 10 | 20.43 | 2-(2,2,3-Trimethylcyclopent-3-en-1-yl) acetaldehyde | C10H16O | 152.23 | 4.89 |
| 11 | 20.93 | Pinocarveol | C10H16O | 152.23 | 7.65 |
| 12 | 22.07 | (H) 3-Cyclohexen-1-ol | C7H12O | 112.17 | 13.91 |
| 13 | 22.20 | (R) Benzenemethanol | C7H8O | 108.14 | 6.08 |
| 14 | 22.44 | (R) 3-Cyclohexen-1-methanol | C7H12O | 112.17 | 9.71 |
| 15 | 22.69 | Myrtenal | C10H14O | 150.22 | 13.81 |
| 16 | 23.08 | 3-Cyclohexen-1-ol,5-methylene-6-(1-methylethenyl)-acetate | C12H16O2 | 192.25 | 2.53 |
| 17 | 24.11 | Carvone | C10H14O | 150.22 | 5.94 |
| 18 | 25.25 | Phellandral | C10H16O | 152.23 | 3.15 |
| 19 | 25.55 | Isobornyl acetate | C12H20O2 | 196.29 | 9.26 |
| 20 | 28.00 | Neryl acetate | C12H20O2 | 196.29 | 2.86 |
| 21 | 28.12 | Carvyl acetate | C12H18O2 | 194.27 | 17.77 |
| 22 | 28.71 | Geranyl acetate | C12H20O2 | 196.29 | 3.11 |
| 23 | 29.01 | (R) Copaene | C10H16 | 136.23 | 5.21 |
| 24 | 29.35 | Cyclohexane | C6H12 | 84.16 | 14.67 |
| 25 | 29.74 | Dodecanal | C10H24O | 184.32 | 7.93 |
| 26 | 31.50 | Nerylacetone | C13H22O | 194.31 | 6.16 |
| 27 | 33.00 | 1,2,4a,5,6,8a-Hexahydro-1-isopropyl-4,7-dimethylnaphthalene | C15H24 | 204.35 | 25.49 |
| 28 | 33.18 |
| C13H20O | 192.30 | 3.89 |
| 29 | 33.58 | Bicyclo [4.4.0] dec-2-ene-4-ol,2-methyl-9-(prop-1-en-3-ol-2-yl)-6-[1-(hydroxymethyl)vinyl]-4,8a-dimethyl-1,2,4a,5,6,7,8,8a-octahydro-2-naphthalenol | C15H24O2 | 236.35 | 5.16 |
| 30 | 33.96 | 1,2,4a,5,6,8a-Hexahydro-1-isopropyl-4,7-dimethylnaphthalene | C15H24 | 204.35 | 4.56 |
| 31 | 34.14 | 1-Methyl-4-(6-methylhepta-1,5-dien-2-yl) cyclohex-1-ene | C15H24 | 204.35 | 4.40 |
| 32 | 34.36 | 1-Methyl-4-(1,2,2-trimethylcyclopentyl) benzene | C15H22 | 202.33 | 10.72 |
| 33 | 34.65 | 4-Isopropenyl-4,7-dimethyl-1-oxaspiro[2.5]octane | C12H20O | 180.29 | 3.83 |
| 34 | 34.96 | 1,6-Dimethyl-4-isopropyltetralin | C15H22 | 202.33 | 6.20 |
| 35 | 35.89 | (H) | C15H22 | 200.32 | 2.81 |
| 36 | 36.43 | Caryophyllene epoxide | C15H24O | 220.35 | 22.88 |
| 37 | 37.38 |
| C15H24O | 220.35 | 5.27 |
| 38 | 37.56 | Tricyclo [5.2.2.0(1,6)]undecan-3-ol, 2-methylene-6,8,8-trimethyl-2-methylene-6,8,8-trimethyl-tricyclo[5.2.2.0(1,6)]undecan-3-ol | C15H24O | 220.35 | 88.77 |
| 39 | 37.76 | Isoaromadendrene epoxide | C15H24O | 220.35 | 17.44 |
| 40 | 37.88 | 6-methyl-3-[(2Z)-6-methylhepta-2,5-dien-2-yl]-7-oxabicyclo[4.1.0]heptane | C15H24O | 220.35 | 100 |
| 41 | 38.30 | Jasmoline I | C21H30O3 | 330.50 | 18.61 |
| 42 | 39.03 | Schembl21824483 | C15H24O | 220.35 | 24.81 |
| 43 | 39.58 | 1-Oxaspiro[2.5]octane,5,5-dimethyl-4-(3-methyl-1,3-butadienyl)-5,5-dimethyl-4-[(1E)-3-methyl-1,3-butadienyl]-1-oxaspiro[2.5] octane | C14H22O | 206.32 | 11.21 |
| 44 | 39.68 | Patchoulane | C15H26 | 206.37 | 6.35 |
| 45 | 39.99 | (R) Caryophyllene | C15H24 | 204.35 | 6.89 |
| 46 | 40.18 | 3,7,11-Trimethyldodeca-6,10-dien-1-yn-3-ol | C15H24O | 220.35 | 5.31 |
| 47 | 40.72 | Aromadendrene oxide-(2) | C15H24O | 220.35 | 8.85 |
| 48 | 40.93 | (H) Caryophyllene oxide | C15H24O | 220.35 | 14.58 |
| 49 | 41.03 | (7S,9As)-4,4,7,9a-Tetramethyl-1,2,3,6,8,9-hexahydrobenzo [7] annulen-7-ol | C15H26O | 222.37 | 20.96 |
| 50 | 41.23 | 1,2-Bis(ethenyl)-4-propan-2-ylidenecyclohexane | C13H20 | 176.30 | 12.97 |
| 51 | 41.87 | 4a,10a-Methanophenanthren-9 | C18H24O2 | 272.38 | 6.97 |
| 52 | 42.16 | Diepicedrene-1-oxide | C15H24O | 220.35 | 11.10 |
| 53 | 42.44 | 7R,8R-8-Hydroxy-4-isopropylidene-7-methylbicyclo [5.3.1] undec-1-ene | C15H24O | 220.35 | 27.61 |
| 54 | 43.27 | (H) 10,12-Tricosadiynoic acid | C23H38O2 | 364.50 | 9.58 |
| 55 | 43.46 | (H) Cubenol | C15H26O | 222.37 | 6.40 |
| 56 | 44.98 | 4,6,6-Trimethyl-2-[(1E)-3-methylbuta-1,3-dienyl]-3-oxatricyclo [5.1.0.02,4] octane | C15H22O | 218.33 | 8.16 |
| 57 | 46.48 | (H) Andrographolide | C20H30O5 | 350.40 | 7.45 |
| 58 | 49.34 | 6,10,14-Trimethylpentadecan-2-one | C18H36O | 268.50 | 29.74 |
| 59 | 49.45 | Boronal | C14H22O | 206.32 | 5.41 |
| 60 | 52.84 | Farnesylacetone | C18H30O5 | 262.40 | 6.55 |
| 61 | 60.97 | 2(3H)-Furanone, dihydro-5-undecyl | C15H28O2 | 240.38 | 4.51 |
| 62 | 67.61 | (R) Heptacosane | C27H56 | 380.70 | 2.98 |
| 63 | 70.89 | 1-(4-Bromobutyl)-2-piperidinone | C9H16BrNO | 234.13 | 3.58 |
Figure 1Effect on improving the symptom of SE in rats with epilepsy KA-induced. (a) SE% of epilepsy rats after treatment. (b) Seizure core of epilepsy rats after treatment. Compared with CON and sham groups, the difference was significant (#P < 0.05). Compared with the MOD group, the difference was significant (∗P < 0.05).
Figure 2Effect on the pathological changes in KA-induced epilepsy rats with treatment. (a) HE staining in the hippocampus.. (b) Nissl staining in the hippocampus.
Figure 3Effect on the expression of GFAP in KA-induced epilepsy rats with treatment.
Figure 4Effect on the changes of neurotransmitter levels in KA-induced epilepsy rats with treatment. (a) The content of GABA AR in KA-induced epilepsy rats with treatment; (b) the content of GAD65 in KA-induced epilepsy rats with treatment; (c) the content of GAD67 in KA-induced epilepsy rats with treatment; (d) the content of GFAP in KA-induced epilepsy rats with treatment; (e) the content of GIRK1 in KA-induced epilepsy rats with treatment; and (f) the content of NMDAR1 in KA-induced epilepsy rats with treatment.
Figure 5The effect of BAO on hippocampal neuron model of epilepsy. (a) The cell viability of different doses of BAO. (b) The effect of different doses of BAO on hippocampal neuron model of epilepsy. Compared with the model group, the difference was significant (∗P < 0.05).
Figure 6Effect on the expression of apoptosis and inflammatory proteins in KA-induced epilepsy rats with treatment. (a) The content of caspase 3 in KA-induced epilepsy rats with treatment; (b) the content of COX2 in KA-induced epilepsy rats with treatment; (c) the content of TLR 4 in KA-induced epilepsy rats with treatment; and (d) the content of HMBG1 in KA-induced epilepsy rats with treatment.
Figure 7BAO through apoptosis pathway regulation attenuated KA-induced epilepsy-like behavior. (a) Western blotting in KA-induced epilepsy rats with treatment; (b) the expression of Bcl2 in KA-induced epilepsy rats with treatment; (c) the expression of Bax in KA-induced epilepsy rats with treatment; and (d) the expression of caspase 3 in KA-induced epilepsy rats with treatment.
Figure 8BAO through apoptosis pathway regulation attenuated the hippocampal neuron model of epilepsy. (a) Western blotting in hippocampal neuron model of epilepsy with treatment; (b) the expression of Bcl2 in hippocampal neuron model of epilepsy with treatment; (c) the expression of Bax in hippocampal neuron model of epilepsy with treatment; and (d) the expression of caspase 3 in hippocampal neuron model of epilepsy rats with treatment.
Figure 9BAO through GABA pathway regulation attenuated KA-induced epilepsy-like behavior. (a) Western blotting in KA-induced epilepsy rats with treatment; (b) the expression ofGAD65 in KA-induced epilepsy rats with treatment; (c) the expression of GAD67 in KA-induced epilepsy rats with treatment; (d) the expression of GIRK1 in KA-induced epilepsy rats with treatment; (e) the expression of GFAP in KA-induced epilepsy rats with treatment; and (f) the expression of GABA AR in KA-induced epilepsy rats with treatment.
Figure 10BAO through GABA pathway regulation attenuated the hippocampal neuron model of epilepsy. (a) Western blotting in hippocampal neuron model of epilepsy with treatment; (b) the expression of GABA AR in hippocampal neuron model of epilepsy with treatment; (c) the expression of GAD 65 in hippocampal neuron model of epilepsy with treatment; (d) the expression of GAD67 in hippocampal neuron model of epilepsy rats with treatment; and (f) the expression of GIRK1 in hippocampal neuron model of epilepsy rats with treatment.
Figure 11BAO through Notch/NMDAR pathway regulation attenuated KA-induced epilepsy-like behavior. (a) Western blotting in KA-induced epilepsy rats with treatment; (b) the expression of Notch1 in KA-induced epilepsy rats with treatment; (c) the expression of MAP2 in KA-induced epilepsy rats with treatment; and (d) the expression of NMDAR1 in KA-induced epilepsy rats with treatment.
Figure 12BAO through Notch/NMDAR pathway regulation attenuated hippocampal neuron model of epilepsy. (a) Western blotting in hippocampal neuron model of epilepsy with treatment; (b) the expression of Notch 1 in hippocampal neuron model of epilepsy with treatment; (c) the expression of MAP 2 in hippocampal neuron model of epilepsy with treatment; (d) the expression of NMDAR1 in hippocampal neuron model of epilepsy rats with treatment.
Figure 13The mechanisms of the aerial parts of B. chinense aromatic oil attenuate kainic acid-induced epilepsy-like behavior.